Page 1637 - Saunders Comprehensive Review For NCLEX-RN

nephrotoxicity- or ototoxicity-
producing medications.
3. Side and adverse effects
a. Hypersensitivity
b. Pain and irritation at the injection site

c. Nephrotoxicity is indicated by

increased blood urea nitrogen and
serum creatinine levels.

d. Ototoxicity is indicated by

tinnitus, dizziness, ringing or roaring
in the ears, and reduced hearing.

e. Neurotoxicity is indicated by

headache, dizziness, lethargy, tremors,
and visual disturbances.
f. Superinfections
4. Interventions
a. Assess for hypersensitivity.

b. Monitor for ototoxic, neurotoxic,

and nephrotoxic reactions.

c. Monitor liver and renal function

test results.
d. Obtain baseline audiometric test and
repeat every l to 2 months, because the
medication impairs the eighth cranial
nerve.
e. Assess acuteness of hearing.
f. Monitor for visual changes.
g. Assess hydration status and maintain
adequate hydration during therapy.
h. Monitor intake and output.
i. Assess urinalysis.
j. Monitor for superinfection.

5. Client education: To notify the PHCP if hearing

loss, changes in vision, or urinary problems occur
E. Ethionamide
1. Description
a. Mechanism of action is unknown.
b. Used to treat MDR-TB when significant
resistance to other medications is
expected

1637